What is Fresenius Med Cr's earnings per share (EPS)?

Fresenius Med Cr (FMS) reported diluted earnings per share of $4.06 for fiscal year 2016. This represents a 20.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fresenius Med Cr Financials

FMS

FY2016 annual

Revenue $17.9B +7.0% YoY

Net Income $1.2B +20.8% YoY

EPS (Diluted) $4.06 +20.1% YoY

Free Cash Flow $1.1B +10.2% YoY

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2016 Currency USD FYE December

Fresenius Med Cr (FMS) reported $17.9B in revenue for fiscal year 2016, up 7.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FMS FY2016 2026-08-15

Fresenius Medical Care’s cash-generative care model paired with gradual deleveraging turned modest margin gains into sturdier earnings in FY2016.

From FY2015 to FY2016, operating margin rose from 13.9% to 14.7%. At the same time, interest expense fell to $452M, so profit improved not just because sales increased, but because both operating efficiency and financing drag moved in the right direction together.

FY2016 operating cash flow of $2.14B comfortably exceeded net income, which is a useful earnings-quality signal because reported profit was backed by cash collection. But capital spending of $1.03B absorbed nearly half of that operating cash, showing this is not an effortlessly asset-light model.

The balance sheet became a bit more self-funded: debt to equity eased from 0.8x to 0.7x as equity grew and long-term debt declined. Even so, goodwill at $13.7B represents about half of total assets, so a large share of the asset base reflects past acquisitions rather than hard assets that directly fund liquidity.

Financial Health Signals

Financial health score not available

Fresenius Med Cr does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Grey Zone

2.08

Fresenius Med Cr scores 2.08, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Fresenius Med Cr passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.72x

For every $1 of reported earnings, Fresenius Med Cr generates $1.72 in operating cash flow ($2.1B OCF vs $1.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.83x

Fresenius Med Cr earns $5.83 in operating income for every $1 of interest expense ($2.6B vs $452.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$17.9B

YoY+7.0%

5Y CAGR+7.3%

Fresenius Med Cr generated $17.9B in revenue in fiscal year 2016. This represents an increase of 7.0% from the prior year.

EBITDA

$3.4B

YoY+12.1%

5Y CAGR+5.3%

Fresenius Med Cr's EBITDA was $3.4B in fiscal year 2016, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.1% from the prior year.

Net Income

$1.2B

YoY+20.8%

5Y CAGR+3.0%

Fresenius Med Cr reported $1.2B in net income in fiscal year 2016. This represents an increase of 20.8% from the prior year.

EPS (Diluted)

$4.06

YoY+20.1%

5Y CAGR+3.0%

Fresenius Med Cr earned $4.06 per diluted share (EPS) in fiscal year 2016. This represents an increase of 20.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.1B

YoY+10.2%

5Y CAGR+5.5%

Fresenius Med Cr generated $1.1B in free cash flow in fiscal year 2016, representing cash available after capex. This represents an increase of 10.2% from the prior year.

Cash & Debt

$747.2M

YoY+36.0%

5Y CAGR+10.3%

Fresenius Med Cr held $747.2M in cash against $7.2B in long-term debt as of fiscal year 2016.

Dividends Per Share

$0.80

YoY+2.6%

Fresenius Med Cr paid $0.80 per share in dividends in fiscal year 2016. This represents an increase of 2.6% from the prior year.

Shares Outstanding

306M

YoY+0.3%

5Y CAGR+0.4%

Fresenius Med Cr had 306M shares outstanding in fiscal year 2016. This represents an increase of 0.3% from the prior year.

Margins & Returns

Gross Margin

32.3%

YoY+0.4pp

5Y CAGR-0.8pp

Fresenius Med Cr's gross margin was 32.3% in fiscal year 2016, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.

Operating Margin

14.7%

YoY+0.8pp

5Y CAGR-1.8pp

Fresenius Med Cr's operating margin was 14.7% in fiscal year 2016, reflecting core business profitability. This is up 0.8 percentage points from the prior year.

Net Margin

6.9%

YoY+0.8pp

5Y CAGR-1.6pp

Fresenius Med Cr's net profit margin was 6.9% in fiscal year 2016, showing the share of revenue converted to profit. This is up 0.8 percentage points from the prior year.

Return on Equity

11.5%

YoY+1.1pp

5Y CAGR-2.1pp

Fresenius Med Cr's ROE was 11.5% in fiscal year 2016, measuring profit generated per dollar of shareholder equity. This is up 1.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$162.4M

YoY+15.7%

5Y CAGR+7.9%

Fresenius Med Cr invested $162.4M in research and development in fiscal year 2016. This represents an increase of 15.7% from the prior year.

Capital Expenditures

$1.0B

YoY+8.1%

5Y CAGR+11.5%

Fresenius Med Cr invested $1.0B in capex in fiscal year 2016, funding long-term assets and infrastructure. This represents an increase of 8.1% from the prior year.

Share Buybacks

Not reported for fiscal year 2016.

FMS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

FMS annual income statement

Metric	FY16	FY15	FY14	FY13	FY12	FY11	FY10	FY09	FY08	FY07
Revenue	$17.9B+7.0%	$16.7B+217.9%	$5.3B+5.9%	$5.0B-64.0%	$13.8B+9.8%	$12.6B+6.1%	$11.8B+5.3%	$11.2B+6.0%	$10.6B+9.2%	$9.7B
Cost of Revenue	$12.1B+6.4%	$11.4B+5.3%	$10.8B+9.8%	$9.9B+7.3%	$9.2B+9.3%	$8.4B+5.1%	$8.0B+8.0%	$7.4B+6.2%	$7.0B+9.7%	$6.4B
Gross Profit	$5.8B+8.4%	$5.3B+195.7%	-$5.6B-13.7%	-$4.9B-206.5%	$4.6B+10.8%	$4.2B+8.3%	$3.8B+0.1%	$3.8B+5.6%	$3.6B+8.1%	$3.4B
R&D Expenses	$162.4M+15.7%	$140.3M+14.9%	$122.1M-2.9%	$125.8M+12.7%	$111.6M+0.7%	$110.8M+14.8%	$96.5M+2.9%	$93.8M+16.9%	$80.2M+20.6%	$66.5M
SG&A Expenses	$3.0B+5.1%	$2.9B+9.5%	$2.6B+11.0%	$2.4B+7.1%	$2.2B+11.1%	$2.0B+9.8%	$1.8B-8.2%	$2.0B+5.9%	$1.9B+9.8%	$1.7B
Operating Income	$2.6B+13.4%	$2.3B+3.2%	$2.3B-0.1%	$2.3B+1.7%	$2.2B+6.9%	$2.1B+7.9%	$1.9B+9.6%	$1.8B+5.0%	$1.7B+5.8%	$1.6B
Interest Expense	$452.2M-11.0%	$508.0M+2.6%	$495.4M+10.7%	$447.5M-4.9%	$470.5M+32.0%	$356.4M+16.7%	$305.5M-4.9%	$321.4M-11.1%	$361.6M-9.5%	$399.6M
Income Tax	$683.1M+9.8%	$622.1M+6.6%	$583.6M-1.4%	$592.0M-2.2%	$605.1M+0.7%	$601.1M+3.9%	$578.3M+17.9%	$490.4M+3.1%	$475.7M+4.8%	$453.8M
Net Income	$1.2B+20.8%	$1.0B-1.5%	$1.0B-5.8%	$1.1B-6.5%	$1.2B+10.8%	$1.1B+9.5%	$978.5M+9.8%	$891.1M+9.0%	$817.6M+14.0%	$717.1M
EPS (Diluted)	$4.06+20.1%	$3.38-2.0%	$3.45-5.5%	$3.65-5.7%	$3.87+10.3%	$3.51+8.3%	$3.24+8.4%	$2.99+9.1%	$2.74+13.2%	$2.42

Metric	Q4'16	Q3'16	Q2'16	Q1'16	Q4'15	Q3'15	Q2'15	Q1'15
Revenue	$4.7B+1.9%	$4.6B+4.0%	$4.4B+5.1%	$4.2B-49.4%	$8.3B+96.2%	$4.2B+0.8%	$4.2B+10.6%	$3.8B
Cost of Revenue	$3.1B-1.0%	$3.1B+3.5%	$3.0B+4.7%	$2.9B+0.3%	$2.9B+1.0%	$2.8B-1.8%	$2.9B-99.9%	$2.8T
Gross Profit	$1.6B+8.2%	$1.5B+5.2%	$1.4B+6.1%	$1.3B-75.7%	$5.4B+292.6%	$1.4B+6.5%	$1.3B+100.0%	-$2.8T
R&D Expenses	$42.2M-3.8%	$43.9M+13.2%	$38.8M+3.4%	$37.5M-6.2%	$39.9M+14.3%	$34.9M+1.3%	$34.5M-99.9%	$30.9B
SG&A Expenses	$767.2M-2.5%	$786.8M+7.5%	$732.1M-3.5%	$758.5M-2.2%	$775.7M+4.5%	$742.3M+2.7%	$722.6M-99.9%	$654.9B
Operating Income	$786.2M+17.4%	$669.9M+4.5%	$641.1M+18.7%	$540.3M-18.4%	$661.8M+7.9%	$613.5M+12.2%	$547.0M-99.9%	$504.4B
Interest Expense	$106.0M-3.5%	$109.9M-8.4%	$119.9M+3.0%	$116.4M-6.8%	$124.9M+17.9%	$105.9M-8.0%	$115.1M-99.9%	$162.0B
Income Tax	$212.2M+29.2%	$164.2M-2.5%	$168.4M+21.8%	$138.3M-23.4%	$180.5M+7.1%	$168.4M+24.4%	$135.4M-99.9%	$137.9B
Net Income	$388.1M+16.5%	$333.2M+13.3%	$293.9M+28.9%	$228.0M-28.0%	$316.8M+20.8%	$262.3M+9.0%	$240.8M-99.9%	$209.5B
EPS (Diluted)	N/A	N/A	N/A	$0.75	N/A	$0.86	N/A	$0.69

FMS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

FMS annual balance sheet

Metric	FY16	FY15	FY14	FY13	FY12	FY11	FY10	FY09	FY08	FY07
Total Assets	$26.9B+6.2%	$25.4B-0.1%	$25.4B+9.8%	$23.1B+3.6%	$22.3B+14.3%	$19.5B+14.3%	$17.1B+8.0%	$15.8B+6.0%	$14.9B	N/A
Current Assets	$7.3B+8.1%	$6.8B+0.7%	$6.7B+6.9%	$6.3B+2.6%	$6.1B+7.6%	$5.7B+10.5%	$5.2B+9.0%	$4.7B+12.2%	$4.2B	N/A
Cash & Equivalents	$747.2M+36.0%	$549.5M-13.3%	$633.9M-7.2%	$682.8M-0.8%	$688.0M+50.5%	$457.3M-12.5%	$522.9M+73.6%	$301.2M+35.9%	$221.6M-9.4%	$244.7M
Inventory	$1.4B+5.2%	$1.3B+20.2%	$1.1B+1.7%	$1.1B+5.8%	$1.0B+7.2%	$967.5M+19.6%	$809.1M-1.5%	$821.7M+16.2%	$707.0M	N/A
Accounts Receivable	$3.5B+7.3%	$3.3B+2.5%	$3.2B+5.5%	$3.0B+0.6%	$3.0B+7.9%	$2.8B+8.7%	$2.6B+12.6%	$2.3B+5.0%	$2.2B	N/A
Goodwill	$13.7B+4.9%	$13.0B-0.4%	$13.1B+12.2%	$11.7B+2.1%	$11.4B+24.3%	$9.2B+5643.5%	$159.9M-97.9%	$7.5B+2.8%	$7.3B	N/A
Total Liabilities	$14.2B+2.9%	$13.8B-4.7%	$14.5B+11.9%	$13.0B+3.1%	$12.6B+13.9%	$11.1B+19.1%	$9.3B+5.7%	$8.8B-0.1%	$8.8B	N/A
Current Liabilities	$5.0B+21.4%	$4.1B+19.3%	$3.5B-2.2%	$3.6B+12.1%	$3.2B-25.6%	$4.3B+12.5%	$3.8B+45.2%	$2.6B-17.0%	$3.1B	N/A
Long-Term Debt	$7.2B-8.3%	$7.9B-12.9%	$9.0B+16.4%	$7.7B-0.5%	$7.8B+41.7%	$5.5B+27.5%	$4.3B-2.7%	$4.4B+11.9%	$4.0B	N/A
Total Equity	$10.8B+9.3%	$9.9B+4.7%	$9.4B+2.3%	$9.2B+3.3%	$8.9B+13.2%	$7.9B+7.1%	$7.4B+10.5%	$6.7B+12.0%	$6.0B+7.1%	$5.6B
Retained Earnings	$8.8B+12.3%	$7.9B+10.8%	$7.1B+11.4%	$6.4B+14.6%	$5.6B+19.7%	$4.6B+20.5%	$3.9B+24.0%	$3.1B+26.9%	$2.5B	N/A

Metric	Q4'16	Q3'16	Q2'16	Q1'16	Q4'15	Q3'15	Q2'15	Q1'15
Total Assets	$26.9B+1.0%	$26.7B+0.4%	$26.6B+1.9%	$26.1B+2.8%	$25.4B-0.2%	$25.4B0.0%	$25.4B-99.9%	$25.1T
Current Assets	$7.3B+1.3%	$7.2B-0.8%	$7.3B+1.8%	$7.1B+5.6%	$6.8B+0.1%	$6.8B+0.9%	$6.7B-99.9%	$6.6T
Cash & Equivalents	$747.2M+18.6%	$629.8M-12.9%	$722.7M+39.6%	$517.8M-5.8%	$549.5M-11.6%	$621.4M+6.7%	$582.2M-99.9%	$622.9B
Inventory	$1.4B+0.2%	$1.4B+1.6%	$1.4B-0.1%	$1.4B+3.3%	$1.3B+1.6%	$1.3B+9.3%	$1.2B-99.9%	$1.2T
Accounts Receivable	$3.5B-2.7%	$3.6B+4.4%	$3.5B-3.7%	$3.6B+9.6%	$3.3B-0.1%	$3.3B+0.8%	$3.3B-99.9%	$3.2T
Goodwill	$13.7B+1.3%	$13.5B+0.5%	$13.4B+2.1%	$13.2B+0.9%	$13.0B0.0%	$13.0B-0.3%	$13.1B-99.9%	$13.0T
Total Liabilities	$14.2B+0.3%	$14.2B-2.1%	$14.5B+2.3%	$14.2B+2.4%	$13.8B-2.6%	$14.2B-1.1%	$14.4B-99.9%	$14.1T
Current Liabilities	$5.0B-4.1%	$5.3B+6.8%	$4.9B+10.6%	$4.4B+7.2%	$4.1B+5.5%	$3.9B+8.8%	$3.6B-99.9%	$3.5T
Long-Term Debt	$7.2B+0.4%	$7.2B-6.9%	$7.7B-1.8%	$7.8B-0.1%	$7.9B-6.0%	$8.4B-5.1%	$8.8B-99.9%	$8.6T
Total Equity	$10.8B+2.1%	$10.6B+4.0%	$10.2B-0.1%	$10.2B+3.1%	$9.9B+2.7%	$9.6B+0.6%	$9.6B-99.9%	$9.6T
Retained Earnings	$8.8B+4.6%	$8.4B+4.1%	$8.1B+0.2%	$8.1B+2.9%	$7.9B+4.2%	$7.6B+3.6%	$7.3B-99.9%	$7.3T

FMS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

FMS annual cash flow statement

Metric	FY16	FY15	FY14	FY13	FY12	FY11	FY10	FY09	FY08	FY07
Operating Cash Flow	$2.1B+9.2%	$2.0B+5.3%	$1.9B-8.5%	$2.0B-0.2%	$2.0B+41.0%	$1.4B+5.7%	$1.4B+2.2%	$1.3B+31.7%	$1.0B-15.3%	$1.2B
Capital Expenditures	$1.0B+8.1%	$952.9M+2.3%	$931.6M+24.6%	$747.9M+10.8%	$675.3M+13.0%	$597.9M+14.2%	$523.6M-8.7%	$573.6M-16.5%	$687.4M+20.0%	$572.7M
Free Cash Flow	$1.1B+10.2%	$1.0B+8.3%	$929.8M-27.7%	$1.3B-5.6%	$1.4B+60.7%	$848.6M+0.5%	$844.5M+10.4%	$765.0M+132.5%	$329.0M-47.5%	$626.9M
Investing Cash Flow	-$1.4B-37.8%	-$1.0B+62.8%	-$2.7B-123.2%	-$1.2B+47.2%	-$2.3B+2.8%	-$2.3B-108.5%	-$1.1B-61.2%	-$698.0M+21.7%	-$891.4M-14.7%	-$777.0M
Financing Cash Flow	-$584.8M+42.0%	-$1.0B-225.2%	$805.0M+199.6%	-$808.0M-272.5%	$468.3M-41.0%	$793.2M+5489.4%	-$14.7M+97.4%	-$558.1M-257.6%	-$156.1M+54.2%	-$340.7M
Dividends Paid	-$277.2M-5.3%	-$263.2M+17.2%	-$317.9M-7.4%	-$296.1M-209.0%	$271.7M-3.2%	$280.6M+21.0%	$232.0M0.0%	$231.9M-8.1%	$252.4M+34.0%	$188.4M

Metric	Q4'16	Q3'16	Q2'16	Q1'16	Q4'15	Q3'15	Q2'15	Q1'15
Operating Cash Flow	$843.6M+92.2%	$438.9M-35.2%	$677.6M+276.9%	$179.8M-67.2%	$548.3M-5.3%	$579.3M	$0-100.0%	$832.5B
Capital Expenditures	$282.4M+16.9%	$241.5M-68.1%	$756.3M+202.3%	-$250.2M-18.1%	$305.6M+33.1%	$229.6M-72.5%	$835.5M-99.8%	-$417.8B
Free Cash Flow	$561.2M+184.4%	$197.3M+351.0%	-$78.6M-11.7%	-$70.4M-129.0%	$242.7M-30.6%	$349.7M+141.9%	-$835.5M-100.2%	$414.7B
Investing Cash Flow	-$451.4M-65.6%	-$272.6M+14.4%	-$318.2M+5.6%	-$337.1M-39.7%	-$241.3M+14.4%	-$281.8M	$0+100.0%	-$477.6B
Financing Cash Flow	-$266.9M-0.2%	-$266.5M-60.3%	-$166.3M-244.7%	$114.9M+130.8%	-$373.3M-55.2%	-$240.5M	$0+100.0%	-$393.8B
Dividends Paid	-$554.4M-200.0%	$554.4M+300.0%	-$277.2M	$0+100.0%	-$526.5M-200.0%	$526.5M+100.0%	$263.2M+100.1%	-$263.2B

Not reported in any period shown, so not listed: Share Buybacks.

FMS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

FMS annual financial ratios

Metric	FY16	FY15	FY14	FY13	FY12	FY11	FY10	FY09	FY08	FY07
Gross Margin	32.3%+0.4pp	31.9%	-105.8%	-98.6%-131.9pp	33.3%+0.3pp	33.0%+0.7pp	32.4%-1.7pp	34.1%-0.1pp	34.2%-0.3pp	34.5%
Operating Margin	14.7%+0.8pp	13.9%-28.9pp	42.8%-2.6pp	45.4%+29.3pp	16.1%-0.4pp	16.5%+0.3pp	16.2%+0.6pp	15.6%-0.2pp	15.8%-0.5pp	16.3%
Net Margin	6.9%+0.8pp	6.2%-13.7pp	19.9%-2.5pp	22.3%+13.7pp	8.6%+0.1pp	8.5%+0.3pp	8.3%+0.3pp	7.9%+0.2pp	7.7%+0.3pp	7.4%
Return on Equity	11.5%+1.1pp	10.4%-0.7pp	11.1%-0.9pp	12.0%-1.3pp	13.3%-0.3pp	13.6%+0.3pp	13.3%-0.1pp	13.4%-0.4pp	13.7%+0.8pp	12.9%
Return on Assets	4.6%+0.6pp	4.1%-0.1pp	4.1%-0.7pp	4.8%-0.5pp	5.3%-0.2pp	5.5%-0.2pp	5.7%+0.1pp	5.6%+0.2pp	5.5%	N/A
Current Ratio	1.45-0.2x	1.63-0.3x	1.93+0.2x	1.77-0.2x	1.93+0.6x	1.340.0x	1.36-0.5x	1.81+0.5x	1.34	N/A
Debt-to-Equity	0.67-0.1x	0.79-0.2x	0.95+0.1x	0.840.0x	0.87+0.2x	0.70+0.1x	0.58-0.1x	0.660.0x	0.66	N/A
FCF Margin	6.2%+0.2pp	6.0%-11.6pp	17.7%-8.2pp	25.9%+16.0pp	9.9%+3.1pp	6.8%-0.4pp	7.1%+0.3pp	6.8%+3.7pp	3.1%-3.4pp	6.5%

Metric	Q4'16	Q3'16	Q2'16	Q1'16	Q4'15	Q3'15	Q2'15	Q1'15
Gross Margin	34.0%+2.0pp	32.0%+0.4pp	31.6%+0.3pp	31.3%-34.0pp	65.3%+32.7pp	32.7%+1.8pp	30.9%	-73007.1%
Operating Margin	16.8%+2.2pp	14.6%+0.1pp	14.5%+1.6pp	12.8%+4.9pp	8.0%-6.5pp	14.5%+1.5pp	13.0%	13284.2%
Net Margin	8.3%+1.0pp	7.2%+0.6pp	6.7%+1.2pp	5.4%+1.6pp	3.8%-2.4pp	6.2%+0.5pp	5.7%	5518.8%
Return on Equity	3.6%+0.4pp	3.1%+0.3pp	2.9%+0.6pp	2.2%-1.0pp	3.2%+0.5pp	2.7%+0.2pp	2.5%+0.3pp	2.2%
Return on Assets	1.4%+0.2pp	1.3%+0.1pp	1.1%+0.2pp	0.9%-0.4pp	1.3%+0.2pp	1.0%+0.1pp	0.9%+0.1pp	0.8%
Current Ratio	1.45+0.1x	1.37-0.1x	1.48-0.1x	1.610.0x	1.63-0.1x	1.72-0.1x	1.850.0x	1.86
Debt-to-Equity	0.670.0x	0.68-0.1x	0.760.0x	0.770.0x	0.79-0.1x	0.87-0.1x	0.920.0x	0.90
FCF Margin	12.0%+7.7pp	4.3%+6.1pp	-1.8%-0.1pp	-1.7%-4.6pp	2.9%-5.3pp	8.3%+28.2pp	-19.9%	10921.8%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin.

Similar Companies

Tenet Healthcare Corp THC

$22.6B

Encompass Health Corp EHC

$11.9B

Univ Health Svc UHS

$10.4B

Hca Healthcare Inc HCA

$92.9B

Davita Inc DVA

$11.1B

Where Fresenius Med Cr Ranks

Frequently Asked Questions

What is Fresenius Med Cr's annual revenue?

Fresenius Med Cr (FMS) reported $17.9B in total revenue for fiscal year 2016. This represents a 7.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Fresenius Med Cr's revenue growing?

Fresenius Med Cr (FMS) revenue grew by 7.0% year-over-year, from $16.7B to $17.9B in fiscal year 2016.

Is Fresenius Med Cr profitable?

Yes, Fresenius Med Cr (FMS) reported a net income of $1.2B in fiscal year 2016, with a net profit margin of 6.9%.

What is Fresenius Med Cr's EBITDA?

Fresenius Med Cr (FMS) had EBITDA of $3.4B in fiscal year 2016, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Fresenius Med Cr have?

As of fiscal year 2016, Fresenius Med Cr (FMS) had $747.2M in cash and equivalents against $7.2B in long-term debt.

What is Fresenius Med Cr's gross margin?

Fresenius Med Cr (FMS) had a gross margin of 32.3% in fiscal year 2016, indicating the percentage of revenue retained after direct costs of goods sold.

What is Fresenius Med Cr's operating margin?

Fresenius Med Cr (FMS) had an operating margin of 14.7% in fiscal year 2016, reflecting the profitability of core business operations before interest and taxes.

What is Fresenius Med Cr's net profit margin?

Fresenius Med Cr (FMS) had a net profit margin of 6.9% in fiscal year 2016, representing the share of revenue converted into profit after all expenses.

Does Fresenius Med Cr pay dividends?

Yes, Fresenius Med Cr (FMS) paid $0.80 per share in dividends during fiscal year 2016.

What is Fresenius Med Cr's return on equity (ROE)?

Fresenius Med Cr (FMS) has a return on equity of 11.5% for fiscal year 2016, measuring how efficiently the company generates profit from shareholder equity.

What is Fresenius Med Cr's free cash flow?

Fresenius Med Cr (FMS) generated $1.1B in free cash flow during fiscal year 2016. This represents a 10.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Fresenius Med Cr's operating cash flow?

Fresenius Med Cr (FMS) generated $2.1B in operating cash flow during fiscal year 2016, representing cash generated from core business activities.

What are Fresenius Med Cr's total assets?

Fresenius Med Cr (FMS) had $26.9B in total assets as of fiscal year 2016, including both current and long-term assets.

What are Fresenius Med Cr's capital expenditures?

Fresenius Med Cr (FMS) invested $1.0B in capital expenditures during fiscal year 2016, funding long-term assets and infrastructure.

How much does Fresenius Med Cr spend on research and development?

Fresenius Med Cr (FMS) invested $162.4M in research and development during fiscal year 2016.

How many shares does Fresenius Med Cr have outstanding?

Fresenius Med Cr (FMS) had 306M shares outstanding as of fiscal year 2016.

What is Fresenius Med Cr's current ratio?

Fresenius Med Cr (FMS) had a current ratio of 1.45 as of fiscal year 2016, which is considered adequate.

What is Fresenius Med Cr's debt-to-equity ratio?

Fresenius Med Cr (FMS) had a debt-to-equity ratio of 0.67 as of fiscal year 2016, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Fresenius Med Cr's return on assets (ROA)?

Fresenius Med Cr (FMS) had a return on assets of 4.6% for fiscal year 2016, measuring how efficiently the company uses its assets to generate profit.

What is Fresenius Med Cr's Altman Z-Score?

Fresenius Med Cr (FMS) has an Altman Z-Score of 2.08, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Fresenius Med Cr's Piotroski F-Score?

Fresenius Med Cr (FMS) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Fresenius Med Cr's earnings high quality?

Fresenius Med Cr (FMS) has an earnings quality ratio of 1.72x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Fresenius Med Cr cover its interest payments?

Fresenius Med Cr (FMS) has an interest coverage ratio of 5.83x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.